FACTORS ASSOCIATED WITH PRESCRIBING OF TERIFLUNOMIDE AND DIMETHYL FUMARATE VERSUS FINGOLIMOD IN MULTIPLE SCLEROSIS

被引：0
|
作者：
Earla, J. r [1 ]
Hutton, G. J. [2 ]
Aparasu, R. R. [3 ]
机构：
[1] Univ Houston, Coll Pharm, Fords, NJ USA
[2] Baylor Coll Med, McNair Campus, Houston, TX 77030 USA
[3] Univ Houston, Coll Pharm, Houston, TX 77030 USA
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HSD13
引用
收藏
页码：S482 / S482
页数：1
相关论文
共 50 条
  • [41] Increased Multiple Sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate
    Delgado, Silvia
    Hernandez, Jeffrey
    Tornes, Leticia
    Rammohan, Kottil
    NEUROLOGY, 2019, 92 (15)
  • [42] Dimethyl fumarate for multiple sclerosis
    Papadopoulou, Athina
    D'Souza, Marcus
    Kappos, Ludwig
    Yaldizli, Oezguer
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 19 (12) : 1603 - 1612
  • [43] Assessment of fingolimod versus dimethyl fumarate for the treatment of multiple sclerosis; a 24-month follow-up study
    Masjedi, Samane-Sadat
    Etemadifar, Masoud
    Zadeh, Nadia Mohammad
    Afzali, Mahdieh
    AMERICAN JOURNAL OF CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2021, 10 (03) : 86 - 92
  • [44] Persistence with fingolimod versus dimethyl fumarate in patients with multiple sclerosis: retrospective analysis of US open source pharmacy data
    Bergvall, N.
    Lahoz, R.
    Nazareth, T.
    Korn, J. R.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 196 - 196
  • [45] Multiple sclerosis patients initiating dimethyl fumarate versus fingolimod in the real-world setting have baseline characteristics associated with worse clinical prognosis
    Hersh, C.
    Lei, Y.
    de Moor, C.
    Rudick, R.
    Williams, J. R.
    Kieseier, B.
    Koulinska, I.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 866 - 867
  • [46] Liver injury associated with dimethyl fumarate in multiple sclerosis patients
    Munoz, Monica A.
    Kulick, Corrinne G.
    Kortepeter, Cindy M.
    Levin, Robert L.
    Avigan, Mark I.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (14) : 1947 - 1949
  • [47] The effects of dimethyl fumarate and fingolimod on T-cell lymphocyte proliferation in patients with multiple sclerosis
    Reynolds, Audrey
    Gaughan, Maria
    Holden, Dean
    Redenbaugh, Vyanka
    Dunne, Jean
    Redmond, Janice
    Conlon, Niall
    IRISH JOURNAL OF MEDICAL SCIENCE, 2022, 191 (06) : 2759 - 2762
  • [48] Characterization of lymphopenia in relapsing-remitting multiple sclerosis patients treated with dimethyl fumarate and fingolimod
    Nakhaei-Nejad, M.
    Barilla, D.
    Lee, C-H.
    Blevins, G.
    Giuliani, F.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 618 - 618
  • [49] Comparison of natalizumab vs fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: two year experience
    Vollmer, B. L.
    Nair, K. V.
    Sillau, S.
    Corboy, J.
    Vollmer, T.
    Alvarez, E.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 856 - 857
  • [50] The effects of dimethyl fumarate and fingolimod on T-cell lymphocyte proliferation in patients with multiple sclerosis
    Audrey Reynolds
    Maria Gaughan
    Dean Holden
    Vyanka Redenbaugh
    Jean Dunne
    Janice Redmond
    Niall Conlon
    Irish Journal of Medical Science (1971 -), 2022, 191 : 2759 - 2762
12345